To include your compound in the COVID-19 Resource Center, submit it here.

EC approves Novartis' Kisqali for breast cancer

The European Commission approved Kisqali ribociclib (LEE011) from Novartis AG (NYSE:NVS; SIX:NOVN) for use in combination with

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE